Congress Materials – Team PHenomenal Hope 2024
2024 Team PHenomenal Hope | Dec 6 | Boston, MA
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Expert consensus on patient engagement strategies and shared decision-making to improve patient outcomes in pulmonary arterial hypertension ENCORE
Ryan JJ, Lombardi S, Saggar R, Wilson M, Han M, Benninger C, Lam J, Cho M, Stone M, Bridge D, Perry R, Enstone A, Smith H, Perrett L, Doad G
This poster will be available after December 6, 2024
Insights into methamphetamine-associated pulmonary arterial hypertension: An analysis of medical and pharmacy claims data
de Jesus Perez V, Kingrey J, Hardy WD, Tan G, Adhia A, Lopez D, Cho M, Sandros M, Ryan JJ
This poster will be available after December 6, 2024
Patient perspectives on fixed dose combination therapy for pulmonary hypertension: exploratory focus group insights
Elwing JM, Barta S, Smith T, Gomez Rendon G, Lopez D, Peters P, Sandros M, Muralidhar A
This poster will be available after December 6, 2024
Patient preferences regarding the use of combination ERA+PDE5i for the treatment of pulmonary arterial hypertension: Results from a discrete choice experiment. ENCORE
Wilson M, Kolaitis NA, Kingman M, Gomez Rendon G, Lopez D, Rahman M, Paoli CJ, Martin A, McGarvey N, Lee A, Mirza S , Melendres-Groves L
This poster will be available after December 6, 2024
Perceptions of the prostacyclin pathway: Insights from a pulmonary arterial hypertension patient engagement research council ENCORE
Han M, Doad G, Massaad R, McConnell W
This poster will be available after December 6, 2024
Predictive value of pulmonary artery pulsatility index in pulmonary arterial hypertension: REVEAL analysis
Ruopp NF, Farber H, Tobore T, Rahman M, Yen J, Kapur N, Safdar Z
This poster will be available after December 6, 2024
Prior authorization restrictiveness negatively impacts time to receipt of endothelin receptor antagonist therapy for pulmonary arterial hypertension (PAH) ENCORE
Chakinala M, Panjabi S, Casorso J, Azam S, Malinowski J, Holler E, Kapoor V, Meyers J, Oudiz RJ
This poster will be available after December 6, 2024
Pulmonary arterial hypertension clinical trial endpoints and outcomes: Patient perspectives and preferences
Gomberg-Maitland M, Ventetuolo C, Adhia A, Yen J, Ryan JJ, Lewis D, Cho M, Panjabi S, Saggar R
This poster will be available after December 6, 2024
Racial and ethnic differences in PAH care: Insights from a multicenter study in the United States
Han M, Doad G, Lam J, Cho M, Duran V, Frick A, Chakinala M, Farber H
This poster will be available after December 6, 2024
Through the patient lens: The diagnostic journey from connective tissue disease to pulmonary arterial hypertension ENCORE
Highland KB, Chakravarty R, Georgi S, Han M
This poster will be available after December 6, 2024
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.